Next Article in Journal
Systemic Vulnerability, as Expressed by I-CAM and MMP-9 at Presentation, Predicts One Year Outcomes in Patients with Acute Myocardial Infarction—Insights from the VIP Clinical Study
Next Article in Special Issue
Basal Septal Hypertrophy as the Early Imaging Biomarker for Adaptive Phase of Remodeling Prior to Heart Failure
Previous Article in Journal
Dentin Growth after Direct Pulp Capping with the Different Fractions of Plasma Rich in Growth Factors (PRGF) vs. MTA: Experimental Study in Animal Model
Previous Article in Special Issue
Novel Biomarkers in Heart Failure: New Insight in Pathophysiology and Clinical Perspective
 
 
Review
Peer-Review Record

Biomarkers in Cardiorenal Syndrome

J. Clin. Med. 2021, 10(15), 3433; https://doi.org/10.3390/jcm10153433
by Giovanni Goffredo 1,2, Roberta Barone 1,2, Vito Di Terlizzi 1,2, Michele Correale 1,2, Natale Daniele Brunetti 1,2 and Massimo Iacoviello 1,2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2021, 10(15), 3433; https://doi.org/10.3390/jcm10153433
Submission received: 18 July 2021 / Accepted: 29 July 2021 / Published: 31 July 2021
(This article belongs to the Special Issue Novel Biomarkers in Heart Failure)

Round 1

Reviewer 1 Report

The authors have adequately addressed the reviewers concern. The review is more comprehensively addresses the literature around biomarkers in cardiorenal syndrome.

Reviewer 2 Report

The authors addressed appropriately all my queries.

Back to TopTop